Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls

Brain Research Bulletin

Volumn 83, Issue 5, 2010, Pages 232-237

  van Duijn, Erik ^a,b   Selis, Mischa A ^a   Giltay, Erik J ^a   Zitman, Frans G ^a   Roos, Raymund A C ^a   van Pelt, Hans ^c   van der Mast, Rose C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Center for Mental Health Care Delfland   (Netherlands)

^c U Diagnostics BV   (Netherlands)

Author keywords

Cortisol; Huntington's disease; Hypothalamic pituitary adrenal axis; Movement disorder; Neurodegenerative disease; Saliva

Indexed keywords

HYDROCORTISONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEXAMETHASONE SUPPRESSION TEST; ENDOCRINE FUNCTION; FEMALE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOM;

ADULT; CIRCADIAN RHYTHM; FEMALE; HUMANS; HUNTINGTON DISEASE; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PITUITARY-ADRENAL SYSTEM; SALIVA;

EID: 77957679394     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.08.006     Document Type: Article

References (37)

1. American Psychiatric Association The dexamethasone suppression test: an overview of its current status in psychiatry. The APA task force on laboratory tests in psychiatry. Am. J. Psychiatry 1987, 144:1253-1262.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR 2000, American Psychiatric Association, Washington DC.
3. Aziz N.A., Swaab D.F., Pijl H., Roos R.A.C. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev. Neurosci. 2007, 18:223-251.
4. Aziz N.A., Fronczek R., Maat-Schieman M., Unmehopa U., Roelandse F., Overeem S., van Duinen S., Lammers G.J., Swaab D.F., Roos R.A.C. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008, 18:474-483.
5. Aziz N.A., Pijl H., Fröhlich M., van der Graaf A.W.M., Roelfsema F., Roos R.A.C. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab. 2009, 94:1223-1228.
6. Björkqvist M., Petersén Å., Bacos K., Isaacs J., Norlén P., Gil J., Popovic N., Sundler F., Bates G.P., Tabrizi S.J., Brundin P., Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1713-1721.
7. Clow A., Thorn L., Evans P., Hucklebridge F. The awakening cortisol response: methodological issues and significance. Stress 2004, 7:29-37.
8. De Souza E.B., Whitehouse P.J., Folstein S.E., Price D.L., Vale W.W. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Res. 1987, 437:355-359.
9. Federenko I., Wüst S., Hellhammer D.H., Dechoux R., Kumsta R., Kirschbaum C. Free cortisol awakening responses are influenced by awakening time. Psychoneuroendocrinology 2004, 29:174-184.
10. Folstein M., Folstein S.E., McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
11. Healy D.G., Harkin A., Cryan J.F., Kelly J.P., Leonard B.E. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology 1999, 145:303-308.
12. Heuser I.J.E., Chase T.N., Mouradian M.M. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol. Psychiatry 1991, 30:943-952.
13. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
14. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
15. Huntington Study Group Unified huntington's disease rating scale: reliability and consistency. Mov. Disord. 1996, 11:136-142.
16. Jahn H., Schick M., Kiefer F., Kellner M., Yassouridis A., Wiedemann K. Metyrapone as additive treatment in major depression. Arch. Gen. Psychiatry 2004, 61:1235-1244.
17. Kassubek J., Juengling F.D., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P., Aschoff A.J., Ludolph A.C., Landwehrmeyer G.B. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 2004, 75:213-220.
18. Kremer H.P.H., Roos R.A.C., Dingjan G.M., Marani E., Bots G.T.A.M. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 1990, 49:371-382.
19. Kremer H.P.H., Roos R.A.C., Dingjan G.M., Bots G.T.A.M., Bruyn G.W., Hofman M.A. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci. Lett. 1991, 132:101-104.
20. Kremer H.P.H. Clinical neurology of Huntington's disease. Huntington's Disease 2002, 28-61. Oxford University Press, New York. third ed. G. Bates, P. Harper, L. Jones (Eds.).
21. Kurlan R., Caine E., Rubin A., Nemeroff C.B., Bisette G., Zaczek R., Coyle J., Spielman F.J., Irvine C., Shoulson I. Cerebrospinal fluid correlates of depression in Huntington's disease. Arch. Neurol. 1988, 45:881-883.
22. Leblhuber F., Peichl M., Neubauer C., Reisecker F., Steinparz F.X., Windhager E., Maschek W. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J. Neurol. Sci. 1995, 132:76-79.
23. Markianos M., Panas M., Kalfakis N., Vassilopoulos D. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease. Neuroendocrinol. Lett. 2007, 28:199-203.
24. Miller G.E., Chen E., Zhou E.S. I fit goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol Bull. 2007, 133:25-45.
25. Petersén Å., Gil J., Maat-Schieman M.L., Björkqvist M., Tanila H., Araújo I.M., Smith R., Popovic N., Wierup N., Norlén P., Li J.Y., Roos R.A.C., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14:39-47.
26. Petersén Å., Björkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 2006, 24:961-967.
27. Politis M., Pavese N., Tai Y.F., Tabrizi S.J., Barker R.A., Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008, 131:2860-2869.
28. Pruessner J.C., Wolf O.T., Hellhammer D.H., Buske-Kirschbaum A., von Auer K., Jobst S., Kaspers F., Kirschbaum C. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997, 61:2539-2549.
29. Pruessner J.C., Kirschbaum C., Meinlschmid G., Hellhammer D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
30. Saleh N., Moutereau S., Durr A., Krystkowiak P., Azulay J.-P., Tranchant C., Brousolle E., Morin F., Bachoud-Lévi A.-C., Maison P. Neuroendocrine disturbances in Huntington's disease. PLoS ONE 2009, 4(3):e4962. 10.1371/journal.pone.0004962.
31. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
32. Tsigos C., Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 2002, 53:865-871.
33. van Duijn E., Kingma E.M., Timman R., Zitman F.G., Tibben A., Roos R.A.C., van der Mast R.C. Cross-sectional study on prevalence of psychiatric disorders in Huntington's disease, in comparison with mutation-negative siblings. J. Clin. Psychiatry 2008, 11:1804-1810.
34. Vassos E., Panas M., Kladi A., Vassilopoulos D. Effect of CAG repeat length on psychiatric disorders in Huntington's disease. J. Psychiatr. Res. 2008, 42:544-549.
35. Wood N.I., Goodman A.O., van der Burg J.M., Gazeau V., Brundin P., Björkqvist M., Petersén Å., Tabrizi S.J., Barker R.A., Morton A.J. Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res. Bull. 2008, 76:70-79.
36. World Health Organization Composite International Diagnostic Interview [computer program] version 2.1 1997, World Health Organization, Geneva, Translation: M.H. ter Smitten, R.M.W. Smeets W. van den Brink.
37. Wüst S., Wolf J., Hellhammer D.H., Federenko I., Schommer N., Kirschbaum C. The cortisol awakening response-normal values and confounds. Noise Health 2000, 2:79-88.